Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nuclear Medicine and Biology

• Publication date

  2003-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0969-8051(02)00452-3PMID 12745014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The automated radiosynthesis of [18F]FP-TZTP.

  2003cited by this paper
• Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes.

  2002cited by this paper
• Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-[2-[4-(2-methoxylphenyl)piperazino]ethyl]-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes.

  2001cited by this paper
• Fluoro analogs of WAY-100635 with varying pharmacokinetics properties.

  2000cited by this paper
• PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635.

  2000cited by this paper
• Development of fluorine-18-labeled 5-HT1A antagonists.

  1999cited by this paper
• Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands.

  1999cited by this paper
• In vivo muscarinic binding of 3‐(alkylthio)‐3‐thiadiazolyl tetrahydropyridines

  1999influential reference
• Quantitative functional brain imaging with positron emission tomography

  1998cited by this paper
• Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies

  1998cited by this paper
• PET for drug development and evaluation

  1995cited by this paper
• Radioligand Disposition and Metabolism — Key Information in Early Drug Development

  1995cited by this paper
• Preparation of 18F-labeled muscarinic agonist with M2 selectivity.

  1995cited by this paper
• Radiopharmaceuticals for positron emission tomography : methodological aspects

  1993cited by this paper

• Plasma radio-metabolite analysis of PET tracers for dynamic PET imaging: TLC and autoradiography

  2020cites this paper
• Sample preparation techniques for radiometabolite analysis of positron emission tomography radioligands; trends, progress, limitations and future prospects

  2019cites this paper
• F-FCWAY , a serotonin 1 A receptor radioligand , is a substrate for ef fl ux transport at the human blood-brain barrier

  2016cites this paper
• First-inHuman Evaluation of 18 F-Mefway , a PET Radioligand Specific to Serotonin-1 A Receptors

  2014cites this paper
• First-in-Human Evaluation of 18F-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors

  2014cites this paper
• [(18)F]Fallypride: metabolism studies and quantification of the radiotracer and its radiometabolites in plasma using a simple and rapid solid-phase extraction method.

  2013cites this paper
• A simplified radiometabolite analysis procedure for PET radioligands using a solid phase extraction with micellar medium.

  2013cites this paper
• Effective MicroPET imaging of brain 5‐HT1A receptors in rats with [18F]MeFWAY by suppression of radioligand defluorination

  2012cites this paper
• Imaging of the muscarinic acetylcholine neuroreceptor in rats with the M2 selective agonist [18F]FP-TZTP.

  2012cites this paper
• Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-11C]WAY-100635 in human plasma: an HPLC-assay which enables measurement of two patients in parallel.

  2012influential citation
• A rapid solid-phase extraction method for measurement of non-metabolised peripheral benzodiazepine receptor ligands, [(18)F]PBR102 and [(18)F]PBR111, in rat and primate plasma.

  2011cites this paper
• Imaging in Neurology Research II: PET Imaging of CNS Disorders

  2011cites this paper
• Caractérisation d'un biomarqueur pour l'étude en tomographie par émission de positons des récepteurs muscariniques de type M2 pour le diagnostic précoce de la maladie d'Alzheimer

  2011cites this paper
• Applications of LC-MS in PET radioligand development and metabolic elucidation.

  2010cites this paper
• Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY.

  2009cites this paper
• A SepPak unit for batch processing serial blood plasma samples for PET

  2007cites this paper
• An automated one-step one-pot [(18)F]FCWAY synthesis: development and minimization of chemical impurities.

  2007cites this paper
• Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY.

  2006cites this paper
• In vivo PET assay of functional P-gp in the blood-brain barrier

  2006cites this paper
• Age and APOE‐ϵ4 genotype influence the effect of physostigmine infusion on the in‐vivo distribution volume of the muscarinic‐2‐receptor dependent tracer [18F]FP‐TZTP

  2006cites this paper
• Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents.

  2005cites this paper
• Synthesis procedure for routine production of [carbonyl-11C]desmethyl-WAY-100635.

  2005cites this paper
• Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.

  2005cites this paper
• Tracer kinetic parametric imaging in PET

  2004cites this paper
• Application of LC-MS to the analysis of new radiopharmaceuticals.

  2003cites this paper